MAPK1 and liver cancer: The RTK-Ras-Raf-MEK-Erk pathway is abnormally active in 30% of liver cancer cases and in ~80% of liver cancer in mice induced by diethylnitrosamine (DEN) [4, 48], suggesting that the liver is a suitable tissue for testing whether activation of Erk alone could cause cancer.